Cargando…

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR

The association of anti-EGFR to gemcitabine and oxaliplatin (GEMOX) chemotherapy did not improve survival in biliary tract carcinoma (BTC) patients. Multiple mechanisms might be involved in the resistance to anti-EGFR. Here, we explored the mutation profile of EGFR extracellular domain (ECD), of tyr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peraldo-Neia, Caterina, Cavalloni, Giuliana, Fenocchio, Elisabetta, Cagnazzo, Celeste, Gammaitoni, Loretta, Cereda, Stefano, Nasti, Guglielmo, Satolli, Maria Antonietta, Aprile, Giuseppe, Reni, Michele, Avallone, Antonio, Spadi, Rosella, Venesio, Tiziana, Martin, Vittoria, Doglioni, Claudio, Frattini, Milo, Aglietta, Massimo, Leone, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774843/ https://www.ncbi.nlm.nih.gov/pubmed/29352306 http://dx.doi.org/10.1371/journal.pone.0191593

Ejemplares similares

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)
por: Lombardi, Pasquale, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
por: Peraldo-Neia, Caterina, et al.
Publicado: (2014)

Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line
por: Peraldo Neia, Caterina, et al.
Publicado: (2016)

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine
por: Varamo, Chiara, et al.
Publicado: (2019)

Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient
por: Cavalloni, Giuliana, et al.
Publicado: (2015)

Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients
por: Peraldo-Neia, Caterina, et al.
Publicado: (2019)

Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients
por: Cavalloni, Giuliana, et al.
Publicado: (2021)

A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient
por: Peraldo-Neia, Caterina, et al.
Publicado: (2021)

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
por: Ottaiano, Alessandro, et al.
Publicado: (2013)

Role of NEU3 Overexpression in the Prediction of Efficacy of EGFR-Targeted Therapies in Colon Cancer Cell Lines
por: Bovio, Federica, et al.
Publicado: (2020)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
por: Ottaiano, Alessandro, et al.
Publicado: (2018)

Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
por: Sangiolo, Dario, et al.
Publicado: (2014)

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
por: Pignochino, Ymera, et al.
Publicado: (2009)

Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer
por: Casorzo, Laura, et al.
Publicado: (2009)

Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience
por: Fenocchio, Elisabetta, et al.
Publicado: (2019)

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3
por: Forcella, Matilde, et al.
Publicado: (2017)

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma
por: Peraldo-Neia, C., et al.
Publicado: (2018)

A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
por: Jensen, Steffen Grann, et al.
Publicado: (2021)

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2011)

Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors
por: Berrino, Enrico, et al.
Publicado: (2022)

Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients
por: Berrino, Enrico, et al.
Publicado: (2021)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome
por: Calemma, Rosa, et al.
Publicado: (2012)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity
por: Jun, Sei-Yong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ovso42tohu13drpvcu1lkf6v8b